leaders in cancer treatment & research
A Powerful Joint Venture
Targeted Alpha Therapeutics, Inc.(TalphaT) has developed a radioisotope generator system that is being developed into radiopharmaceuticals for cancer therapy by collaborators at Michigan State University.
Niowave, Inc. is a worldwide leader in the research, development, manufacturing, and operation of superconducting electron linear accelerators for medical radioisotope production.
Michigan State University and Spartan Innovations provides advice, strategy, and administration of program management, customer discovery, marketing efforts and strategic partnerships
The Problem
Bladder cancer was the 12th most prevalent cancer worldwide in 2018, and 17,000 Americans die of the disease each year. Many deaths can be attributed to the lack of effective treatments.
Traditional external beam radiation therapy for bladder cancer is ineffective due to side effects from radiation damage to adjacent tissues, while immunotherapy is well-tolerated but only successful in two-thirds of patients. The remaining 33% of patients with incompletely treated cancer require more radical treatments like bladder removal and systemic chemotherapy. Due to the high number of patients with incomplete responses and the significant morbidity and decreased quality-of-life associated with radical treatments, patients with bladder cancer need new therapies.
Our Solution
TalphaT has developed a novel, highly targeted treatment for bladder cancer with fewer side effects. We combine the specificity of an antibody with the effectiveness of radiation therapy.
Our long-term goal is to increase bladder cancer cures from 67% to 90% while improving patient quality-of-life for over 725,000 Americans living with bladder cancer, especially the 30-40% of patients whose disease is not completely cured by the current standard of care.
Our invention enables safe and effective delivery of targeted alpha-particle therapy for cancer where current standard of care radiation therapy treatments are not possible or ineffective due to off-target toxicity. Learn more…
